

JFW

MAY 21 2004 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel

Application No.: 10/665,971 Group Art Unit: 1642

Filed: September 19, 2003 Examiner: Not yet assigned

Confirmation No.: 5342

Title: METHODS OF TREATING NEURODEGENERATIVE INFLAMMATION WITH CHIMERIC ANTI-TNF ANTIBODIES

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

5-25-04 Dawn M Myers

Date

Signature

Dawn M Myers

Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[] under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

[] under 37 CFR 1.97(c) together with either:

[] a Statement under 37 CFR 1.97(e), as checked below, or

[] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[] under 37 CFR 1.97(d) together with:

- [] a Statement under 37 CFR 1.97(e), as checked below, and
- [] a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- [] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

[] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

- [X] Copies of the cited references AR11, AS11, AT11, AU11, AV11, AW11, AX11, AY11 and AZ11 are enclosed.
- [X] Copies of cited references were entered in prior applications: U.S. Application No. 09/756,398, U.S. Application No. 07/943,852, U.S. Application No. 08/192,093, and U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contain copies of the cited references.
- [] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- [X] The "concise explanation" requirement (non-English references) for references (AQ, AM3, AP3, AM5, AL7, AM7 and AN7) under 37 CFR 1.98(a)(3) is satisfied by:
 - [] the explanation provided on the attached sheet.
 - [] the explanation provided in the Specification.
 - [X] submission of the enclosed Supplementary Partial European Search Report for references AM3 and AP3.

[X] the enclosed English language abstracts for AQ, AM3, AP3, AM5, AL7, AM7 and AN7.

[X] Applicant requests that the following pending applications be considered:

Examiner's
Initials

— U.S. Patent Application No. 09/756,398, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-006.

— U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-008.

— U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010.

— U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012.

— U.S. Patent Application No. 09/927,703, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed August 10, 2001, Docket No.: 0975.1005-013.

— U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed December 7, 2001, Docket No.: 0975.1005-014.

— U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015.

— U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016.

— U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017.

— U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-018.

— U.S. Patent Application No. 10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019.

— U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020.

— U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-021.

— U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022.

— U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023.

— U.S. Patent Application No. 10/208,145, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024.

— U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed August 23, 2002, Docket No.: 0975.1005-025.

— U.S. Patent Application No. 10/319,011, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed December 12, 2002, Docket No.: 0975.1005-029.

— U.S. Patent Application No. 10/371,443, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 21, 2003, Docket No.: 0975.1005-031.

— U.S. Patent Application No. 10/371,962, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 21, 2003, Docket No.: 0975.1005-032.

— U.S. Patent Application No. 10/371,961, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 21, 2003, Docket No.: 0975.1005-033.

— U.S. Patent Application No. 10/379,866, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed March 4, 2003, Docket No.: 0975.1005-034.

— U.S. Patent Application No. 10/774,118, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 6, 2004 Docket No.: 0975.1005-038.

Examiner

Date

- [] A copy of the above-cited applications, including the current claims, is enclosed.
- [X] The specifications for the above cited co-pending applications are substantially identical to the present specification (10/665,971) and the specification of the priority application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed. Therefore, only copies of the current claims for these applications are enclosed. Copies of the specifications of the co-pending applications will be provided upon request.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders
Deirdre Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated:

May 25, 2004

| | | | |
|--|--|---|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 MAY 27 2004 Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, <i>et al.</i> | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

| U.S. PATENT DOCUMENTS | | | | |
|-----------------------|----------|--|--|--|
| EXAMINER INITIAL | REF. NO. | DOCUMENT NUMBER Number-Kind Code (if known) | ISSUE DATE / PUBLICATION DATE MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT |
| | AA | 4,603,106 | 07/29/1986 | Cerami <i>et al.</i> |
| | AB | 4,822,776 | 04/18/1989 | Cerami <i>et al.</i> |
| | AC | 5,658,570 | 08/19/1997 | Newman <i>et al.</i> |
| | AD | 5,750,105 | 05/12/1998 | Newman <i>et al.</i> |
| | AE | 5,231,024 | 07/27/93 | Moeller <i>et al.</i> |
| | AF | 5,223,395 | 06/29/1993 | Gero |
| | AG | 5,436,154 | 07/25/1995 | Barbanti <i>et al.</i> |
| | AH | 5,654,407 | 08/05/1997 | Boyle <i>et al.</i> |
| | AI | 5,700,788 | 12/23/1997 | Mongelli <i>et al.</i> |
| | AJ | 5,730,975 | 03/24/1998 | Hotamisligil <i>et al.</i> |
| | AK | 5,741,488 | 04/21/1998 | Feldman <i>et al.</i> |
| | AA2 | 5,776,947 | 07/07/1998 | Kroemer <i>et al.</i> |
| | AB2 | 6,015,558 | 01/18/2000 | Hotamisligil <i>et al.</i> |
| | AC2 | 6,172,202 B1 | 01/09/2001 | Marcucci <i>et al.</i> |
| | AD2 | 6,194,451 B1 | 02/27/2001 | Alpegiani <i>et al.</i> |
| | AE2 | 5,360,716 | 11/01/1994 | Ohmoto <i>et al.</i> |
| | AF2 | 5,888,511 | 03/30/1999 | Skurkovich <i>et al.</i> |
| | AG2 | 5,958,413 | 09/28/1999 | Anagnostopoulos <i>et al.</i> |
| | AH2 | 5,993,833 | 11/30/1999 | DeLarcharriere <i>et al.</i> |
| | AI2 | 5,342,613 | 08/30/1994 | Creaven <i>et al.</i> |
| | AJ2 | 6,190,691 B1 | 02/20/2001 | Mak |
| | AK2 | 4,816,567 | 03/28/1989 | Cabilly <i>et al.</i> |
| | AA3 | 5,075,236 | 12/24/1991 | Yone <i>et al.</i> |
| | AB3 | 5,959,087 | 09/28/1999 | Rathjen <i>et al.</i> |
| | AC3 | | | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|--|-----------------------------------|
| PTO-1449 REPRODUCED O INFORMATION DISCLOSURE CITATION IN AN APPLICATION MAY 27 2004 May 19, 2004 PATENT & TRADEMARK OFFICE (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER Country Code-Number-Kind Code (if known) | DATE MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT | TRANSLATION YES NO |
|-----|--|--|--------------------|--|----------------------------|
| AL | | EP 0212489A2 | 03/04/1987 | The Rockefeller University | |
| AM | | EP 0218868A2 | 04/22/1987 | New York Blood Center, Inc. | |
| AN | | EP 0288 088 B1 | 03/09/1994 | Teijin Limited | |
| AO | | EP 0308378 B1 | 11/30/1994 | Yeda Research and Development Company Limited | |
| AP | | EP 0380068A1 | 08/01/1990 | Molecular Therapeutics, Inc. | |
| AQ | | EP 0393438A2 | 10/24/1990 | Boehringer Ingelheim International G.M.B.H. | |
| AL2 | | EP 0398327 B1 | 03/15/1995 | Yeda Research and Development Company Limited | |
| AM2 | | EP 0412486 B1 | 11/30/1994 | Yeda Research and Development Company Limited | |
| AN2 | | EP 0433900 B1 | 09/20/1995 | Yeda Research and Development Company Limited | |
| AO2 | | EP 0526905A2 | 02/10/1993 | Yeda Research and Development Company Limited | |
| AP2 | | WO 91/02078 | 02/21/1991 | Peptide Technology LTD | |
| AQ2 | | WO 92/07076 | 04/30/1992 | The Charing Cross Sunley Research Centre | |
| AL3 | | WO 92/13095 | 08/06/1992 | Synergen, Inc. | |
| AM3 | | EP 0260610 B1 | 03/23/1988 | BASF Aktiengesellschaft | |
| AN3 | | WO 91/09967 | 07/11/1991 | Celltech Limited | |
| AO3 | | EP 0351789A2 | 01/24/1990 | Chiron Corporation | |
| AP3 | | EP 0350690A2 | 01/17/1990 | BASF Aktiengesellschaft | |
| AQ3 | | WO 90/00902 | 02/08/1990 | Chiron Corporation | |
| AL3 | | WO 92/11383 | 07/09/1992 | Celltech Limited | |
| AM4 | | WO 93/02108 | 02/04/1993 | IDEC Pharmaceuticals Corporation | |
| AN4 | | WO 92/16553 | 10/01/1992 | New York University | |

EXAMINER

DATE CONSIDERED

| | | | |
|--|--|--|-----------------------------------|
| PTO-1449 REPRODUCED C O P Y MAY 27 2004 SEARCHED & INDEXED SERIALIZED & FILED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER Country Code-Number-Kind Code (if known) | DATE MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT | TRANSLATION YES NO |
|-----|--|--------------------|--|----------------------------|
| AO4 | WO 91/09967 | 07/11/1991 | Celltech Limited | |
| AP4 | EP 0486526B2 | 05/27/1992 | Peptech Limited | |
| AQ4 | EP 0512528 B1 | 11/11/1992 | Yeda Research and Development Company Limited | |
| AL5 | EP 0351789 B1 | 01/24/1990 | Chiron Corporation | |
| AM5 | EP 0453898 A2 | 10/30/1991 | Bayer AG | X |
| AN5 | EP 0585705 A1 | 03/09/1994 | Miles Inc. | |
| AO5 | EP 0614984 A2 | 09/14/1994 | Miles Inc. | |
| AP5 | WO 89/08460 | 09/21/1989 | Celltech Limited | |
| AQ5 | WO 90/01950 | 03/08/1990 | Celltech Limited | |
| AL6 | WO 91/04054 | 04/04/1991 | Millar | |
| AM6 | WO 92/01472 | 02/06/1992 | Celltech Limited | |
| AN6 | WO 93/11236 | 06/10/1993 | Medical Research Council | |
| AO6 | WO 94/08609 | 04/28/1994 | Dana Farber Cancer Institute, Inc. | |
| AP6 | WO 94/08619 | 04/28/1994 | The Kennedy Institute of Rheumatology | |
| AQ6 | WO 92/01059 | 01/23/1992 | Celltech Limited | |
| AL7 | 02-227095 | 09/10/1990 | Otsuka Pharmaceut CO LTD | |
| AM7 | 61-047500 | 03/07/1986 | RES DEV CORP OF JAPAN | |
| AN7 | DE 42 02 665 A1 | 07/29/1993 | Schering AG Berlin und Bergkamen | |
| AO7 | EP 0663836 B1 | 07/09/1997 | The Kennedy Institute of Rheumatology | |

EXAMINER

DATE CONSIDERED

| | | | |
|---|--|--|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION MAY 27 2004 (use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|---|
| AR | Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985). |
| AS | Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985). |
| AT | Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985). |
| AU | Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986). |
| AV | Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987). |
| AW | Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987). |
| AX | Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987). |
| AY | Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987). |
| AZ | Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987). |
| AR2 | Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987). |
| AS2 | Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988). |
| AT2 | Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|---|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, <i>et al.</i> | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|--|
| AU2 | Di Giovine, Francesco, S. <i>et al.</i> , "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988). |
| AV2 | Collins, M.S. <i>et al.</i> , "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting</i> 1989. |
| AW2 | Exley, A.R. <i>et al.</i> , "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989). |
| AX2 | Cross, A.S. <i>et al.</i> , "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J. of Exp. Med.</i> , 169:2021-2027 (1989). |
| AY2 | Engelmann, Hartmut <i>et al.</i> , "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989). |
| AZ2 | Silva, Ayona T. <i>et al.</i> , "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990). |
| AR3 | Opal, Steven M. <i>et al.</i> , "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990). |
| AS3 | Tavernier, Jan <i>et al.</i> , "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990). |
| AT3 | Lucas, R. <i>et al.</i> , "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990). |
| AU3 | Hinshaw, L.B. <i>et al.</i> , "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990). |
| AV3 | Nophar, Yaron <i>et al.</i> , "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|--|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|---|
| AW3 | Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990). |
| AX3 | Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990). |
| AY3 | Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990). |
| AZ3 | Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990). |
| AR4 | Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990). |
| AS4 | Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990). |
| AT4 | Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : <i>In Vitro</i> and <i>In Vivo</i> Application," <i>Cytokine</i> , 2(3):162-169 (1990). |
| AU4 | Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990). |
| AV4 | Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991). |
| AW4 | Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991). |
| AX4 | Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992). |
| AY4 | Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992). |
| AZ4 | Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|---|--|---|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| May 19, 2004 (Use several sheets if necessary) | | FIRST NAMED INVENTOR Junming Le, <i>et al.</i> | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | |
|-----|--|
| AR5 | Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993). |
| AS5 | Aggarwal, Bharat B. <i>et al.</i> , "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985). |
| AT5 | Beutler, B. <i>et al.</i> , "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985). |
| AU5 | Echtenacher, Bernd <i>et al.</i> , "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990). |
| AV5 | Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991). |
| AW5 | Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991). |
| AX5 | Genebank Accession, No. N90300 (November 1, 1989). |
| AY5 | Genebank Accession, No. M32046 (June 15, 1990). |
| AZ5 | Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", <i>Behring Inst. Mitt</i> , No.78:118-132 (1985). |
| AR6 | Whittle, Nigel, <i>et al.</i> , "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," <i>J. Cell Biochem.</i> , Supl. 13A:96 (1989). |
| AS6 | Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," <i>Sem. Immunol.</i> , 2:457-466 (1990). |
| AT6 | Starnes, H. Fletcher, Jr., <i>et al.</i> , "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal <i>Escherichia Coli</i> Infection and Lethal Tumor Necrosis Factor Challenge in Mice," <i>J. Immunol.</i> , 145:4185-4191 (1990). |
| AU6 | Duncombe, Andrew S. <i>et al.</i> , "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," <i>J. Immunol.</i> , 143:3828-3834 (1989). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|---|--|---|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| May 19, 2004 (Use several sheets if necessary) | | FIRST NAMED INVENTOR Junming Le, <i>et al.</i> | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | |
|-----|---|
| AV6 | Aderka, Dan <i>et al.</i> , "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," <i>J. Immunol.</i> , 143:3517-3523 (1989). |
| AW6 | Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," <i>Isr. J. Med. Sci.</i> , 27:52-60 (1991). |
| AX6 | Lassalle, Ph., <i>et al.</i> , "Potential Implication of Endothelial Cells in Bronchial Asthma," <i>Int. Arch Allergy Appl. Immunol.</i> , 94:233-238 (1991). |
| AY6 | Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," <i>Clin. Immunol. Immunopathol.</i> , 55:157-170 (1990). |
| AZ6 | Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor- α at 2.6 Å Resolution," <i>J. Biol. Chem.</i> , 264:17595-17605 (1989). |
| AR7 | Gillies, Stephen D. <i>et al.</i> , "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J. Immunol. Methods</i> , 125:191-202 (1989). |
| AS7 | Kameyama, Koh-zoh, <i>et al.</i> , "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," <i>FEBS Lett.</i> , 244:301-306 (1989). |
| AT7 | Hayashi, H. <i>et al.</i> , "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," <i>Recent Adv. Chemother.</i> , 820-821 (1985). |
| AU7 | Hirai, Makoto <i>et al.</i> , "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. Immunol. Methods</i> , 96:57-62 (1987). |
| AV7 | Sunahara, N. <i>et al.</i> , "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor α and its antibodies using a bacterial cell wall carrier," <i>J. Immunol. Methods</i> , 109:203-214 (1988). |
| AW7 | Oliff, A., <i>et al.</i> , "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," <i>Cell</i> , 50:555-563 (1987). |
| AX7 | Mule, J.J., <i>et al.</i> , "Antitumor Activity of Recombinant Interleukin 6 in Mice," <i>The Journal of Experimental Medicine</i> , 171:629-636 (1990). |
| AY7 | Luettig, B., <i>et al.</i> , "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," <i>The Journal of Immunology</i> , 143:4034-4038 (1989). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|--|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|--|
| AZ7 | Barbuto, J.A.M., et al., "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," <i>Proceedings of the American Association for Cancer Research</i> , 34:487, Abstract 2904, (1993). |
| AR8 | Bendtzen, K., et al., "Auto-Antibodies To IL-1 α and TNF α In Normal Individuals And In Infectious And Immunoinflammatory Disorders," <i>The Physiological and Pathological Effects of Cytokines</i> , 10B:447-452 (1990). |
| AS8 | Fomsgaard, A., et al., "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," <i>Scand. J. Immunol.</i> , 30:219-223 (1989). |
| AT8 | James, K. and Bell, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," <i>Journal of Immunological Methods</i> , 100:5-40 (1987). |
| AU8 | Alberts, B. et al., Molecular Biology of the Cell, Garland Publishing Inc., pp 182-183 (1983). |
| AV8 | Simpson, S.Q., et al., "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," <i>Critical Care Clinics</i> , 5:27-47 (1989). |
| AW8 | Bendtzen, K., et al., "Native inhibitors (autoantibodies) of IL-1 α and TNF," <i>Immunology Today</i> , 10(7):222 (1989). |
| AX8 | Davenport, C., et al., "Stimulation Of Human B Cells Specific For Candida Albicans For Monoclonal Antibody Production," <i>FEMS Microbiol. Immunol.</i> , 4(6):335-343 Abstract (1992). |
| AY8 | Pennica, D., et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> , 312(20/27):724-729 (1984). |
| AZ8 | Gray, P.W., et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," <i>Nature</i> , 312(20/27):721-724 (1984). |
| AR9 | Petersen, C.M., et al., "Bioactive human recombinant tumor necrosis factor- α : an unstable dimer?*", <i>Eur. J. Immunol.</i> , 19:1887-1894 (1989). |
| AS9 | Smith, C. A., et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> , 248:1019-1023 (1990). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|--|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | |
|------|--|
| AT9 | Brennan, F.M., et al., "Inhibitory Effect Of TNF α Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," <i>The Lancet</i> , 244-247 (1989). |
| AU9 | Hahn, T., et al., "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," <i>Proc. Natl. Acad. Sci. USA</i> 82:3814-3818 (1985). |
| AV9 | Grau, G.E., et al., "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," <i>Science</i> , 237:1210-1212 (1987). |
| AW9 | Barbanti, E., et al., "A high-affinity neutralizing anti-human TNF-alpha monoclonal antibody that cross-reacts with human TNF-beta," <i>Abstracts</i> , March 6th-9th (1991). |
| AX9 | Jones, E.Y., et al., "Structure of tumour necrosis factor," <i>Nature</i> , 338:225-228 (1989). |
| AY9 | Clark, W. R., "Types of Antibody Reactions," In <i>The Experimental Foundations of Modern Immunology</i> , (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991). |
| AZ9 | Beutler, B., et al., "Cachectin and tumour necrosis factor as two sides of the same biological coin," <i>Nature</i> , 320:584-588 (1986). |
| AR10 | Folks, T. M., et al., "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," <i>Proc. Natl. Acad. Sci. USA</i> , 86:2365-2358 (1989). |
| AS10 | Hird, V., et al., "Immunotherapy with Monoclonal Antibodies," In <i>Genes and Cancer</i> (John Wiley & Sons, Ltd.)(1990). |
| AT10 | Rhein, R., "Another sepsis drug down-Immunex' TNF receptor," <i>Biotechnology Newswatch</i> , Monday, October 4, 1993, pp. 1,3. |
| AU10 | Boyle, P., et al., "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α ," <i>Cellular Immunology</i> , 152:556-568 (1993). |
| AV10 | Boyle, P., et al., "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF α on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," <i>Cellular Immunology</i> , 152:569-581 (1993). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|--|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, et al. | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|------|---|
| AW10 | Sheehan, K.C.F., et al., "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," <i>The Journal of Immunology</i> , 142(11):3884-3893 (1989). |
| AX10 | Jacob, C.O., et al., "Tumour necrosis factor- α in murine autoimmune 'lupus' nephritis," <i>Nature</i> , 331:356-358 (1988). |
| AY10 | Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", <i>Hybridoma</i> , 19(6):463-471 (2000). |
| AZ10 | Paul, W.E. (Ed.), <i>Fundamental Immunology</i> , 3 rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993). |
| AR11 | Beck, J., et al., "Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?", <i>Acta Neurol Scand.</i> , 78: 318-323 (1988). |
| AS11 | Beck, J., et al., "Increased Production of TNF- α in Multiple Sclerosis," <i>Immunobiology</i> , 175(1-2): 91-92 (1987) Abstract. |
| AT11 | Selmaj, K. et al., "Tumor Necrosis Factor Mediates Myelin Damage in Organotypic Cultures of Nervous Tissue," <i>Neuroimmunology</i> , 16(1): 159 (1987) Abstract. |
| AU11 | Pardridge, W.M., "New approaches to drug delivery through the blood-brain barrier," <i>Trends in Biotechnology</i> , 12(6): 239-245 (1994). |
| AV11 | Van Oosten, B.W., et al., "Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2," <i>Neurology</i> , 47(6):1531-1534 (1996) Abstract. |
| AW11 | Van Oosten, B.W., et al., "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial," <i>Neurology</i> , 49(2):351-357 (1997) Abstract. |
| AX11 | Arnason, B.G.W., "TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study," <i>Neurology</i> , 53(3):457-465 (1999) Abstract. |
| AY11 | Kassiotis G. and Kollias G., "Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (TNF) at the p55 TNF Receptor Level: Implications for Pathogenesis and Therapy of Autoimmune Demyelination," <i>J. Exp. Med.</i> , 193(4):427-434 (2001). |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

| | | | |
|--|--|---|-----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 19, 2004 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-036 | APPLICATION NO. 10/665,971 |
| | | FIRST NAMED INVENTOR Junming Le, <i>et al.</i> | FILING DATE September 19, 2003 |
| | | EXAMINER Not Assigned | CONFIRMATION NO. 5342 |
| | | | GROUP 1642 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|------|--|
| AZ11 | Selmaj, K, <i>et al.</i> , "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination," <i>Ann. Neurol.</i> (30):694-700 (1991). |
|------|--|

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|